Eli Lilly Launches New Phase III Trial in China for Its Once-Daily Depression Candidate

Stock News08-17 20:50

A new Phase III clinical study evaluating Brenipatide injection in adult participants with depression has been registered by Eli Lilly on August 17, according to the official website of the Drug Clinical Trial Registration and Information Publication Platform.

Data from the Insight database indicates that Brenipatide is the first GLP-1 class product worldwide to initiate a Phase III clinical trial for depression.

Brenipatide is an investigational GLP1R/GIPR dual agonist and represents Eli Lilly's second GLP-1/GIP dual-target drug following tirzepatide. Its highest global development stage is Phase III, and it has not yet received marketing approval.

Beyond depression, Eli Lilly has also initiated two additional Phase III studies of Brenipatide targeting alcohol use disorder. The company is further exploring other indications, including bipolar disorder, asthma, nicotine dependence, schizophrenia, diarrhea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome, and chronic obstructive pulmonary disease, among others.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment